1. At a Glance
On 28 July 2025, Wockhardt announced that its wonder drug Zaynich (Zidebactam/Cefepime, WCK 5222) successfully treated a pan-drug resistant infection in a U.S. liver transplant patient. The case, published in the Journal of Antimicrobial Chemotherapy – AMR, marks a global spotlight moment for Indian pharma innovation.
2. Intro – Why This Matters?
Think of a bacterial infection that laughs at every antibiotic in the doctor’s cabinet. That’s what this U.S. patient had – a pan-drug resistant nightmare caused by Pseudomonas and Klebsiella. Conventional drugs failed, the infection spread, and the transplant was at risk. Enter Zaynich, Wockhardt’s homegrown antibiotic, and suddenly the infection didn’t find it so funny.
3. Deep Dive – What’s the Case?
